Clinical trial · Interventional
Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis
Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis: Correlation Analysis of Prognosis and microRNA Expression
NCT02634502CI-TRIAL-00020246unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore the efficacy and safety of radiofrequency ablation combined with S-1 in pancreatic cancer patients with liver metastasis, as well as the correlation of serum microRNA and patients' prognosis. This protocol will be overseen by the Fudan University Institutional Review Board which has Federal Wide Assurance through the U.S. Department of Health \& Human Services (Approved: April 25, 2002).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Pancreatic | Pancreatic Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiofrequency ablation | Procedure | — | UNRESOLVED |
| S-1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- Patients will receive radiofrequency ablation for liver metastatic lesions, as well as two weeks of oral S-1 treatment every three weeks, until progression of disease or adverse effects leading to termination of treatment. Each 3-week period is one cycle of treatment.
- interventionNames
- Procedure: radiofrequency ablation
- Drug: S-1
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From date of randomization until the date of death, assessed up to 100 months.
Secondary outcomes (1)
- measure
- Progression free survival
- timeFrame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Karnofsky Performance Status ≥ 70 * Histologically/cytologically confirmed pancreatic adenocarcinoma. * Patients must have underwent radical resection of the pancreatic lesion, or have their locally advanced pancreatic lesion controlled after first-line chemotherapy. * At least one measurable liver metastasis by RECIST criteria must be present. * Single liver metastasis smaller than 5cm, or multiple liver metastases less than 6 lesions and smaller than 3cm for each, without metastasis to other sites. * Patients must have adequate organ functions reflected by the laboratory criteria below: Granulocytes ≥ 2,000/uL, Hemoglobin ≥ 8.0 gm/dL, Platelets ≥ 100,000/uL, Serum creatinine \< 2.0 mg/dL, Bilirubin \< 1.5 mg/dL, SGPT \< 2.5 x normal, prothrombin time \<13.5s * Prior therapy, e.g., chemotherapy, radiation, is allowed provided that at least 4 weeks washout time is given. * Patients with jaundice must have a biliary drainage decompression operation before recruitment. * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Prior treatment with S-1. * Liver metastatic lesion is located at the surface of the liver, with more than 1/3 of the tumor protruding outside. * Subject has Child-Pugh grade Class C hepatic impairment, massive ascites, active gastrointestinal bleeding, severe coagulation disorder that could not be corrected, or other contraindication for radiofrequency ablation. * Tumor invasion of Cavity organs. * Known central nervous system involvement and leptomeningeal disease. * Concurrent infection requiring intravenous antibiotics. * Other serious illness or condition including cardiac disease including congestive heart failure (New York Heart Association Classification III or IV), active HIV infection/HIV disease, psychiatric disorders. * Subject has previous or concurrent cancer that is distinct in primary site or histology from pancreatic adenocarcinoma except cervical carcinoma in situ, non-melanoma carcinoma of the skin or in situ carcinoma of the bladder. Any cancer curatively treated greater than 3 years prior to entry is permitted. * Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.